Dr. Bert H O'Neil, MD
Claim this profileCommunity Health Network
Studies Solid Tumors
Studies Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Solid Tumors
CLDN18.2 positive
Stage III
Stage IV
2Cancer
Stage IV
PD-L1 positive
Stage III
Affiliated Hospitals
Clinical Trials Bert H O'Neil, MD is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Ivaltinostat + Capecitabine
for Pancreatic Cancer
This trial tests ivaltinostat with capecitabine in patients with advanced pancreatic cancer who have not worsened after initial treatment. The goal is to find a safe and effective dose and to see if this combination can better control the cancer. Capecitabine is a medication that is converted into another drug in the body, showing better selectivity and tolerability in tumor tissues.
Recruiting3 awards Phase 1 & 211 criteria
More about Bert H O'Neil, MD
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Bert H O'Neil, MD has experience with
- KBP-5209
- ZL-1211
- Trastuzumab
- Aromatase Inhibitor (AI)
- Pertuzumab
- Abemaciclib
Breakdown of trials Bert H O'Neil, MD has run
Solid Tumors
Non-Small Cell Lung Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bert H O'Neil, MD specialize in?
Bert H O'Neil, MD focuses on Solid Tumors and Cancer. In particular, much of their work with Solid Tumors has involved CLDN18.2 positive patients, or patients who are Stage III.
Is Bert H O'Neil, MD currently recruiting for clinical trials?
Yes, Bert H O'Neil, MD is currently recruiting for 4 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Bert H O'Neil, MD has studied deeply?
Yes, Bert H O'Neil, MD has studied treatments such as KBP-5209, ZL-1211, Trastuzumab.
What is the best way to schedule an appointment with Bert H O'Neil, MD?
Apply for one of the trials that Bert H O'Neil, MD is conducting.
What is the office address of Bert H O'Neil, MD?
The office of Bert H O'Neil, MD is located at: Community Health Network, Indianapolis, Indiana 46250 United States. This is the address for their practice at the Community Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.